Dr. Good is a specialist in the field of Neonatal-Perinatal Medicine. She is a Neonatologist-Scientist, Division Chief of Neonatal-Perinatal Medicine and an Associate Professor in the Department of Pediatrics. In addition to her clinical responsibilities of caring for the patients in the Neonatal Critical Care Center, Dr. Good has dedicated her scientific career to understanding the mechanisms regulating intestinal development and the mucosal immune response in the gastrointestinal disease affecting premature infants called necrotizing enterocolitis (NEC).
Education and Training
BS, University of Southern California
MS, American University of the Caribbean
MD, American University of the Caribbean
Residency, Children’s Hospital of Illinois, University of Illinois, College of Medicine
Fellowship, Neonatal-Perinatal Medicine, Children’s Hospital of Pittsburgh, Magee-Women’s Hospital of UPMC University of Pittsburgh School of Medicine
Research
Dr. Good’s Laboratory is focused on the cellular and molecular mechanisms involved in the pathogenesis of a devastating intestinal disease primarily affecting premature infants called necrotizing enterocolitis (NEC). The long-term goal of the Good Lab is to understand the signaling pathways regulating the uncontrolled immune response in NEC and how these responses can be prevented through dietary modifications or targeted intestinal epithelial therapies. Her basic and translational research utilizes a bench-to-bedside approach with multiple cutting-edge techniques. In her pre-clinical studies, their team utilizes a humanized neonatal mouse model of NEC to understand the signaling pathways and immune cell responses involved in NEC development. Specifically, the laboratory interrogates ways to modulate the immune response, epithelial cell and stem cell regeneration as well as early microbial colonization during NEC. In the clinical component of her research program, Dr. Good leads a large multi-center NEC biorepository for the dedicated pursuit of molecular indicators of disease and to gain greater pathophysiologic insights during NEC in humans. Dr. Good also developed a premature infant intestine-on-a-chip model to study NEC and provide a personalized medicine approach to test new therapeutics. Her laboratory is currently funded with multiple NIH R01 grants and has previously received K08 and R03 funding as well as awards from the March of Dimes, the Gerber Foundation and the NEC Society.
